Core Viewpoint - The reclassification of marijuana by President Trump as a Schedule III drug opens up significant opportunities for the cannabis industry, particularly for companies like Scott's Miracle Grow and its Hawthorne subsidiary, which provides cannabis growing supplies [1][4][6]. Company Developments - Scott's Miracle Grow plans to combine its Hawthorne subsidiary with a dedicated pure-play cannabis company next year, indicating a strategic shift to capitalize on the evolving cannabis market [2][12]. - The CEO of Scott's Miracle Grow, Jim Hagadorn, expressed enthusiasm about the executive order, highlighting the culmination of a decade-long effort to achieve this change [3][4]. Industry Implications - The reclassification allows for increased medical research on cannabis, which was previously restricted under Schedule I classification, thus potentially leading to new medical applications and benefits [4][6]. - Legal cannabis businesses can now benefit from a reduced federal tax rate of 21%, down from an 80% rate, which was previously punitive and hindered profitability [6][7]. - The change is expected to help legitimate markets thrive while reducing the influence of illicit operators and protecting children [7][8]. Market Reactions - Following the announcement, there was initial stock price volatility, with some stocks experiencing a spike before settling down, indicating a "sell on the news" reaction from investors [11].